产品分类导航
艾曲波帕
艾曲波帕
艾曲波帕

艾曲波帕

更新时间:2025-02-07

价格:
CAS号: 496775-62-3
药典: 中国药典,美国药典,英国药典,欧洲药典,日本药典,企业标准
级别: 药用级
立即询盘
收藏

产品详情

产品名称: 艾曲波帕
产品分类: 医药中间体
CAS号: 496775-62-3
药典: 中国药典,美国药典,英国药典,欧洲药典,日本药典,企业标准
级别: 药用级
是否为生产商:
主要销售市场: 北美洲,中/南美洲,西欧,东欧,大洋洲,亚洲,中东,非洲
是否提供样品:

产品描述:

Sugar coated tablet, 25mg/50mg. The recommended initial dose is 50mg once daily; For patients with moderate or severe hepatic insufficiency, the recommended initial dose is 25mg once a day, taken before meals (1 hour before or 2 hours after meals).

Thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura, patients with poor response to corticosteroids, immunoglobulin, or splenectomy.

REVOLADE should only be used in patients with ITP whose degree of thrombocytopenia and clinical conditions increase the risk of bleeding. REVOLADE should not be used to normalize normal platelet counts. Eltrombopag is promising for treating aplastic anemia

公司简介

南京萸上生物科技有限公司,注册于江苏省南京市江宁区。专注于提供原料药,中间体,化工产品,新材料,橡、塑制品,原辅材料及其相关服务。相关从业人员均有十五年以上行业经验。除了我们的目录产品以外,我们同时为不同客户提供代理贸易服务。包括橡、塑制品销售及原辅材料供应;植物水解物加工,钢材、石料、锰矿石、污水处理剂、煤炭销售(不含采矿);农副产品、饲料原料、散装食品、预包装食品。 多年来我们的业务一直稳定增长,并继续保持良好的增长势头。我们以良好的研发能力,严格的质量体系,准确迅速的市场反应,以及18年来孜孜不倦服务医药,食品及采矿业的经验为核心价值。

该公司其他产品

4-(Difluoromethoxy)-3-hydroxybenzaldehyde
4-(Difluoromethoxy)-3-hydroxybenzaldehyde
Sugar coated tablet, 25mg/50mg. The recommended initial dose is 50mg once daily; For patients with moderate or severe hepatic insufficiency, the recommended initial dose is 25mg once a day, taken before meals (1 hour before or 2 hours after meals). Thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura, patients with poor response to corticosteroids, immunoglobulin, or splenectomy. REVOLADE should only be used in patients with ITP whose degree of thrombocytopenia and clinical conditions increase the risk of bleeding. REVOLADE should not be used to normalize normal platelet counts. Eltrombopag is promising for treating aplastic anemia
2-Ethoxybenzoic acid
2-Ethoxybenzoic acid
Sugar coated tablet, 25mg/50mg. The recommended initial dose is 50mg once daily; For patients with moderate or severe hepatic insufficiency, the recommended initial dose is 25mg once a day, taken before meals (1 hour before or 2 hours after meals). Thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura, patients with poor response to corticosteroids, immunoglobulin, or splenectomy. REVOLADE should only be used in patients with ITP whose degree of thrombocytopenia and clinical conditions increase the risk of bleeding. REVOLADE should not be used to normalize normal platelet counts. Eltrombopag is promising for treating aplastic anemia
5-(2-ethoxy)-phenyl-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one
5-(2-ethoxy)-phenyl-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one
Sugar coated tablet, 25mg/50mg. The recommended initial dose is 50mg once daily; For patients with moderate or severe hepatic insufficiency, the recommended initial dose is 25mg once a day, taken before meals (1 hour before or 2 hours after meals). Thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura, patients with poor response to corticosteroids, immunoglobulin, or splenectomy. REVOLADE should only be used in patients with ITP whose degree of thrombocytopenia and clinical conditions increase the risk of bleeding. REVOLADE should not be used to normalize normal platelet counts. Eltrombopag is promising for treating aplastic anemia
南京萸上生物科技有限公司
注册资本
公司地址
江苏省南京市江宁区科学园芝兰路18号
联系人
查看联系方式
快速询盘
询盘主题
请输入询盘主题
询盘信息
请输入询盘信息
快速发送询盘
2006-2026 上海博华国际展览有限公司版权所有(保留一切权利) 沪ICP备05034851号-57